Literature DB >> 8630942

Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma.

K Y Lam1, S Y Law, M K So, M Fok, L T Ma, J Wong.   

Abstract

BACKGROUND: Proliferative markers are related to tumor behavior. The commonly used markers are proliferating cell nuclear antigen (PCNA) and Ki-67. The aim of this study is to evaluate the usefulness of MIB-1 (for Ki-67) and PC10 (for PCNA) in the assessment of the clinicopathologic features and prognosis in patients with esophageal squamous cell carcinoma.
METHODS: One hundred patients (88 males, 12 females; mean age, 63 years [range, 39 to 83 years]) with surgically resected esophageal squamous cell carcinoma (32 well differentiated, 51 moderately differentiated, and 17 poorly differentiated) were studied. The clinicopathologic features and survival data of these patients were noted. Representative tissue was collected from each tumor and immunohistochemical preparations for MIB-1 and PC10 were made.
RESULTS: The percentages of cells that tested positive for PC10 and MIB-1 were much higher in tumor cells than in nonneoplastic cells. The pattern of expression of both markers varied with the differentiation of the tumor. The results observed with MIB-1 staining were better than those with PC10; because MIB-1 had less background staining, as well as stronger and more uniform positive signals compared with PC10. Thus, further investigation was performed on MIB-1-stained sections. The tumor cell MIB-1 scores ranged from 169 to 964 positive cells per 1000 cells (mean 598 +/- 211; median, 636). Although it was significantly associated with the differentiation of the tumor (P = 0.0001), the score had no significant relationship to the tumor size, location, or stage, or to the patients' age and sex. The prognosis depended on the size and stage of the lesion. In Stage III lesions (n = 83), patients with MIB-1 scores below 300 had longer actual survival rates than those with a score of 300 or above. However, the survival rates of patients in the latter group were better if the greatest dimension of the tumor diameter was 7.5 cm or less.
CONCLUSIONS: Proliferative activity in esophageal squamous cell carcinoma, as defined by the MIB-1 immunohistochemical method, is significantly related to tumor differentiation. It is also potentially valuable as a prognostic marker in addition to its use in tumor staging and size.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630942     DOI: 10.1002/(SICI)1097-0142(19960101)77:1<7::AID-CNCR3>3.0.CO;2-N

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Use of flow cytometry in the analysis of stage III squamous cell carcinoma of the oesophagus and its association with MIB-1.

Authors:  K Y Lam; L Ma; S Y Law; L K Cheung; T F Luk; J Wong
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

Review 2.  Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy.

Authors:  Hiroshi Okumura; Yasuto Uchikado; Tetsuro Setoyama; Masataka Matsumoto; Tetsuhiro Owaki; Sumiya Ishigami; Shoji Natsugoe
Journal:  Surg Today       Date:  2013-04-19       Impact factor: 2.549

3.  Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma.

Authors:  Yi Ren; Simon Law; Xin Huang; Ping Yin Lee; Michael Bacher; Gopesh Srivastava; John Wong
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

4.  Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki-67 for radiotherapy of oesophageal squamous cell carcinomas.

Authors:  Y Okuno; Y Nishimura; I Kashu; K Ono; M Hiraoka
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

5.  Clinicopathological characteristics of esophageal squamous papillomas in Japanese patients--with comparison of findings from Western countries.

Authors:  Kuniko Takeshita; Shin-Ichi Murata; Shoji Mitsufuji; Naoki Wakabayashi; Keisho Kataoka; Yasunari Tsuchihashi; Takeshi Okanoue
Journal:  Acta Histochem Cytochem       Date:  2006-03-02       Impact factor: 1.938

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.